|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Dipyridamole#Drug Interactions]] |
| {{Dipyridamole}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| No pharmacokinetic drug-drug interaction studies were conducted with Persantine® (dipyridamole USP) tablets. The following information was obtained from the literature.
| |
| | |
| '''Adenosine''': Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.
| |
| | |
| '''Cholinesterase Inhibitors''': Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating '''myasthenia''' gravis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PERSANTINE (DIPYRIDAMOLE) TABLET, COATED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca68879c-0214-4d7c-93b0-bdaf8ef23f8e | publisher = | date = | accessdate = 7 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |